ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) has received approval from the Hong Kong bourse for the listing of 14,114,006 converted H shares, a Thursday filing with the Hong Kong bourse said.
Following the conversion and listing, the biopharmaceutical firm's H shares will rise to 97.29% from 93.83% of its total shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.